Want to see SE:LARK full AI Analyst Report?
CombiGene AB (LARK) Price & Analysis
LARK Stock Chart & Stats
- Day’s Range
- SEK 2.27 - SEK 2.33
- 52-Week Range
- SEK 1.75 - SEK 2.75
- Previous Close
- SEK 2.29
- Volume
- 46.62K
- Average Volume (3M)
- 6,647
- Market Cap
- SEK 45.94M
- Enterprise Value
- SEK 38.38M
- Total Cash (Recent Filing)
- SEK 6.17M
- Total Debt (Recent Filing)
- SEK 0
- Price to Earnings (P/E)
- 39.3
- Beta
- 0.03
- Next Earnings
- Feb 12, 2027
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 86.21%
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance Sheet
A debt-free structure and substantial equity base reduce financial risk and provide resilience while the company advances its programs. This capital position can preserve strategic flexibility and limit financing pressure during continued research and development investment.
Revenue Rebound
The strong TTM revenue rebound indicates improved commercial or partnering-related activity compared with the prior period. If maintained, this growth can broaden the operating base and support progress toward a more durable financial profile, although profitability remains unresolved.
Focused Gene-Therapy Model
A focused neurological gene-therapy pipeline gives CombiGene a defined strategic direction and a business model centered on advancing candidates toward partnerships or licensing. Successful transactions could provide larger partners with commercialization resources beyond the company’s internal scale.
Bears Say
Persistent Cash Burn
Persistent negative operating and free cash flow means the business is not yet self-funding its activities. Continued cash consumption can require additional capital or transactions to sustain development, reducing flexibility even though the balance sheet currently carries no debt.
Negative Core Profitability
Positive net income has not translated into sustainable operating earnings because gross and operating profit remain negative. This weak core profitability limits confidence in recurring earnings power and suggests that the reported improvement may not yet represent a durable operating turnaround.
Volatile Returns
The multi-year pattern of strongly negative return on equity followed by only a slight TTM improvement shows that shareholder returns have been inconsistent. Such volatility makes performance harder to rely on and indicates that the recent improvement has not yet been demonstrated across a sustained period.
LARK FAQ
What was CombiGene AB’s price range in the past 12 months?
What is CombiGene AB’s market cap?
When is CombiGene AB’s upcoming earnings report date?
How were CombiGene AB’s earnings last quarter?
Is CombiGene AB overvalued?
Does CombiGene AB pay dividends?
What is CombiGene AB’s EPS estimate?
How many shares outstanding does CombiGene AB have?
What happened to CombiGene AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of CombiGene AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
CombiGene AB
Lärkberget AB (publ) functions as an investment firm, engaging in a variety of financial endeavors. Its operations encompass direct capital deployment into low-risk instruments, broader financial investments, acquiring stakes in privately held yet profitable companies, and serving as a vehicle for reverse acquisitions. Established in 1990 and based in Östermalm, Sweden, the company transitioned to its current name, Lärkberget AB (publ), in June 2025, having formerly operated as CombiGene AB (publ).
- Sector
- Financial
- Industry
- Asset Management
- CEO
- Peter Ekolind
- Employees
- 1
- Website
- larkberget.se
- Address
- Aboutvalue, Östermalm, AB, 114 34, SE
CombiGene AB (LARK) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 1 | 5 |
| Technical Analysis | 4 | 1 | 5 |
| Moving Averages | 12 | 0 | 0 |